logo
Share SHARE
FONT-SIZE Plus   Neg

Peregrine Says Lung Cancer Trial Data Erroneous - Quick Facts

Peregrine Pharmaceuticals Inc. (PPHM) announced that during the course of preparing for an end-of-phase II meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer, it discovered major discrepancies between some patient sample test results and patient treatment code assignments.

The company stated that due to the double-blind nature of the trial, it was not permitted to have access to either patient group assignments or related product coding information.

As part of the trial's execution, Peregrine contracted with independent third-party contractors to execute treatment group assignments and oversee clinical trial material coding and distribution according to established procedures. A subsequent review of information has determined that the source of these discrepancies appear to have been associated with the independent third-party contracted to code and distribute investigational drug product.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Shares of WM Morrison Supermarkets Plc were gaining more than 4 percent in the early Thursday morning trading as it reported 0.7 percent increase in first-quarter like-for-like sales excluding fuel. LFL sales were up 1.2 percent, including fuel. Zynga Inc. (ZNGA) on Thursday reported a first-quarter loss that narrowed from a year ago, reflecting an increase in revenues despite continued drop in user-base. Earnings for the quarter trumped analysts estimates, as did revenues, sending the company's shares up 13 percent in extended trading hours. San... Shares of Fitbit Inc. (FIT) slumped over 12 percent in extended hours trading after the maker of wearable technology reported a drop in first-quarter profit hurt largely by a surge in operating costs. The company also detailed a weak outlook for the second quarter. Fitbit's profit for the first-quarter...
comments powered by Disqus
Follow RTT